# Evaluation of the Therapeutic Potential of Bioactive Materials Based on a Complex of Oxidovanadium(IV) and Exopolysaccharide Levan in a Model of Insulin Resistance in Mice

**Authors:** Amanda K. J. P. F. da Silva, Eucilene K. de L. B. Marques, Lidiane M. A. de Lima, Widarlane A. S. Alves, Dayane A. Gomes, Pedro L. Guzzo, Mônica F. Belian, Wagner E. Silva, Eduardo C. Lira

PMC · DOI: 10.1002/cmdc.202500754 · Chemmedchem · 2025-12-17

## TL;DR

A new low-toxicity bioactive composition of oxidovanadium(IV) and levan is shown to reduce insulin resistance in mice treated with dexamethasone.

## Contribution

A novel bioactive composition of oxidovanadium(IV) and levan is developed and shown to reduce insulin resistance in a mouse model.

## Key findings

- The composition reduced hyperglycemia by approximately 65% in a dose-dependent manner.
- It also reduced hypertriglyceridemia and the triglyceride/glucose index in mice with dexamethasone-induced insulin resistance.
- The vanadium complex was classified as category 4 in terms of acute toxicity.

## Abstract

Bioactive compositions containing vanadium complexes have been a viable strategy for constructing more biocompatible and less toxic systems. Therefore, this work aim to develop a new composition formed by an oxidovanadium(IV) complex as levan. The acute oral toxicity and insulin resistance (IR) are investigated in an animal model using adult Swiss mice treated with daily injections of the synthetic glucocorticoid dexamethasone. The complex is characterized by electronic absorption (λmax = 771 and 880 nm) and infrared spectroscopies (3359, 3167, 1606, 1342, 1072 cm−1, and the V=O at 937 cm−1); NMR of the 1H, 13C, and 51V (−427, −509, and −529 ppm), and electron paramagnetic resonance (g‐factor = 1.985). The vanadium complex is classified in category 4, according to the acute toxicity protocol. IR in mice is accompanied by a rise in fasting blood glucose at seventh (2.2‐fold) and 14th (threefold) days, triglyceride levels at seventh (2.6‐fold) and 14th (threefold) days, and triglyceride/glucose index (TyG) at seventh (20%) and 14th (25%) days. The bioactive composition attenuated both the hyperglycemia (≈65%) and hypertriglyceridemia and TyG in a dose‐dependent manner. The proposed composition shows promise in reducing IR induced by exogenous corticosteroid treatment.

A low‐toxicity bioactive composition of oxidovanadium(IV) and exopolysaccharide levan is synthesized, characterized, and shown to reduce hyperglycemia, hypertriglyceridemia, and TyG index in a mice model of dexamethasone‐induced insulin resistance.© 2026 WILEY‐VCH GmbH

## Linked entities

- **Chemicals:** dexamethasone (PubChem CID 5743)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** oral toxicity (MESH:D064420), hyperglycemia (MESH:D006943), hypertriglyceridemia (MESH:D015228), IR (MESH:D007333)
- **Chemicals:** dexamethasone (MESH:D003907), glucose (MESH:D005947), 13C (MESH:C000615229), Levan (MESH:C072599), vanadium (MESH:D014639), triglyceride (MESH:D014280), 1H (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913243/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913243/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913243/full.md

---
Source: https://tomesphere.com/paper/PMC12913243